esc semaglutide Frailty and Effects of in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program ESC 2025: evidence of semaglutide

Liraglutide (the active ingredient in Saxenda and Victoza) and semaglutide (the active ingredient in Ozempic) are two of the most studied options, and while they work through the same pathway, they differ in dosing, potency, side effects, and the kind of support they offer over time

It is important to note that in UK coding practice, codes from the T36-T50 range are reserved for poisoning (overdose, wrong substance given or taken in error, or wrong route of administration) and should not be used for adverse effects occurring during correct therapeutic use

up titration of insulin was allowed but not beyond the pre-trial dose

Susan Spratt, an endocrinologist and the senior medical director for the Population Health Management Office at Duke Health in North Carolina